Literature DB >> 10510946

Vascular function in Type 2 diabetes mellitus and pre-diabetes: the case for intrinsic endotheiopathy.

J E Tooke1, K L Goh.   

Abstract

Diabetic angiopathy is a major cause of morbidity and mortality in Type 2 diabetes mellitus (DM). The pathogenesis of vascular complications in this condition appears to be complex, with distinct differences being observed between Type 1 and Type 2 DM. This review outlines the evidence for these differences and identifies endothelial dysfunction as an important associate and antecedent of Type 2DM, which predisposes to characteristic vascular complications and may also have implications for fetal development.

Entities:  

Mesh:

Year:  1999        PMID: 10510946     DOI: 10.1046/j.1464-5491.1999.00099.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  10 in total

1.  Nuclear factor kappa B inhibition improves conductance artery function in type 2 diabetic mice.

Authors:  Modar Kassan; Soo-Kyoung Choi; Maria Galán; Mohamed Trebak; Souad Belmadani; Khalid Matrougui
Journal:  Diabetes Metab Res Rev       Date:  2015-01       Impact factor: 4.876

Review 2.  Microvascular dysfunction: an emerging pathway in the pathogenesis of obesity-related insulin resistance.

Authors:  Dennis M J Muris; Alfons J H M Houben; Miranda T Schram; Coen D A Stehouwer
Journal:  Rev Endocr Metab Disord       Date:  2013-03       Impact factor: 6.514

3.  Acute effects of glucose and insulin on vascular endothelium.

Authors:  D Taubert; A Rosenkranz; R Berkels; R Roesen; E Schömig
Journal:  Diabetologia       Date:  2004-12-15       Impact factor: 10.122

4.  Prevalence of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in Iran: A Systematic Review and Meta-Analysis.

Authors:  Mohsen Kazeminia; Nader Salari; Masoud Mohammadi
Journal:  J Diabetes Res       Date:  2020-09-25       Impact factor: 4.011

5.  Effects of Mesenchymal Stem Cells Therapy on Cardiovascular Risk Factors in Experimental Diabetic Kidney Disease.

Authors:  Einas Nagib Hussein; Gehane M Hamed; Ansam A Seif; Mona A Ahmed; Fatma Abd Elkarim Abu Zahra
Journal:  Can J Kidney Health Dis       Date:  2020-10-22

6.  Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study.

Authors:  Toru Kato; Teruo Inoue; Koichi Node
Journal:  Cardiovasc Diabetol       Date:  2010-03-24       Impact factor: 9.951

7.  Protective effects of scutellarin on type II diabetes mellitus-induced testicular damages related to reactive oxygen species/Bcl-2/Bax and reactive oxygen species/microcirculation/staving pathway in diabetic rat.

Authors:  Lingli Long; Jingnan Wang; Xiaofang Lu; Yuxia Xu; Shuhui Zheng; Canqiao Luo; Yubin Li
Journal:  J Diabetes Res       Date:  2015-03-12       Impact factor: 4.011

8.  Neuropeptide Y1 and alpha-1 adrenergic receptor-mediated decreases in functional vasodilation in gluteus maximus microvascular networks of prediabetic mice.

Authors:  Nicole M Novielli-Kuntz; Kent A Lemaster; Jefferson C Frisbee; Dwayne N Jackson
Journal:  Physiol Rep       Date:  2018-07

9.  Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPARgamma stimulation.

Authors:  Federico Biscetti; Giuseppe Straface; Vincenzo Arena; Egidio Stigliano; Giovanni Pecorini; Paola Rizzo; Giulia De Angelis; Luigi Iuliano; Giovanni Ghirlanda; Andrea Flex
Journal:  Cardiovasc Diabetol       Date:  2009-09-08       Impact factor: 9.951

10.  N-3 polyunsaturated Fatty acids prevent diabetic retinopathy by inhibition of retinal vascular damage and enhanced endothelial progenitor cell reparative function.

Authors:  Maria Tikhonenko; Todd A Lydic; Madalina Opreanu; Sergio Li Calzi; Svetlana Bozack; Kelly M McSorley; Andrew L Sochacki; Matthew S Faber; Sugata Hazra; Shane Duclos; Dennis Guberski; Gavin E Reid; Maria B Grant; Julia V Busik
Journal:  PLoS One       Date:  2013-01-29       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.